XBiotech Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 15, 2024. The filing also presents unaudited quarterly data, including fourth-quarter results. XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies, with a focus on IL-1α therapies and anti-infective candidates. It has no approved products and has not generated product-sales revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $4.0 million |
| Operating expenses | $37.5 million | $37.8 million |
| Operating loss | $37.5 million | $34.5 million |
| Net loss | $24.6 million | $32.9 million |
| Net loss per share | $0.81 | $1.08 |
| Operating cash used | $18.7 million | $14.8 million |
- Revenue fell to zero after the Janssen-related manufacturing agreement ended in November 2022. FY2022 gross profit was $3.4 million, an approximately 84% gross margin; there was no FY2023 revenue or gross margin.
- R&D expense rose 4% to $32.8 million, mainly reflecting increased clinical-trial activity; G&A expense declined 26% to $4.7 million. R&D represented 88% of operating expenses.
- Net loss narrowed despite a larger operating loss, principally as total other income increased to $13.2 million from $0.9 million. This included $10.4 million interest income and a $1.9 million foreign-exchange gain in 2023.
- Cash and cash equivalents were $200.0 million at year-end, up from $157.3 million. Investing cash inflow of $61.5 million largely reflected maturity of time deposits, not operating cash generation. Total assets were $226.6 million; liabilities were $7.8 million. The balance sheet reported no interest-bearing debt at December 31, 2023.
- Management said cash and liquid assets should fund operations and anticipated obligations, and the notes state cash is expected to last at least 12 months from the report date. The company nevertheless expects continuing operating losses and no revenue in 2024.
Quarterly results and material changes
Unaudited Q4 2023 operating loss was $8.6 million, net loss was $4.6 million, and net loss per share was $0.15. Q4 2022 operating loss was $8.2 million, net loss was $3.2 million, and net loss per share was $0.10. The full-year net loss improved year over year, but operating cash use increased and operating loss widened.
Clinical-trial and sponsored-research expense increased to $5.4 million from $2.0 million. The company reported a $4.5 million CEO bonus in 2023, compared with $3.8 million in 2022; the allocation between R&D and G&A changed between years. The 2023 G&A decline also reflected lower share-based compensation, partly offset by higher professional fees related to the June tender offer.
Pipeline, outlook, risks, and unusual items
- Pipeline: The pancreatic-cancer Natrunix study completed data collection in February 2024; data review, database lock, and analysis were still pending, with results expected shortly after data lock. The 210-patient rheumatoid-arthritis study launched in August 2023 and had enrolled about half its participants as of March 2024. Management planned additional rheumatology studies in Q2 2024.
- Hutrukin completed a Phase I study at year-end 2023. The filing reports no significant adverse events, with analysis expected in Q1 2024, and management planned a Phase II stroke study during 2024. These are forward-looking plans, not reported trial outcomes.
- The company also describes a clinical-stage MRSA candidate and preclinical candidates for C. difficile, shingles, and influenza. The filing provides no specific development timelines for these programs.
- In January 2024, after year-end, XBiotech entered a $10 million convertible loan with CEO and founder John Simard to fund construction of a research facility. It bears 8% simple annual interest, is secured by company real estate and cash, and is convertible at $4.048 per share subject to a 19.9% ownership cap. The CEO may elect cash repayment after one year or under specified conditions; independent, disinterested directors approved the agreement.
- The company relaunched plans in Q1 2024 for a 46,000-square-foot R&D facility and a 5,000-square-foot infectious-disease research annex. Construction costs and schedule are not clearly stated in the provided filing text.
- Material risks include clinical and regulatory failure, patient-enrollment delays, lack of product revenue, uncertain future financing needs, competition, dependence on CEO John Simard and key staff, intellectual-property protection, and the possibility that cash runway or development costs differ from management expectations. Up to $600 million in Janssen milestones remain contingent on Janssen’s decisions, approvals, and other conditions; receipt is not assured.
- The 2023 financial statements received an unqualified audit opinion, with no critical audit matters reported. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Current cash, investment balances, spending rate, and whether management’s stated runway remains adequate as trials and facility plans advance.
- Pancreatic-cancer study data and the timing, enrollment, cost, and results of the rheumatoid-arthritis and planned stroke studies.
- Final terms, funding, repayment or conversion status, and collateral implications of the CEO’s $10 million related-party loan.
- Construction budget and commitments for the planned facilities, and whether these expenditures are included in management’s cash-runway assumptions.
- Whether Janssen pursues eligible Bermekimab indications and whether any contingent milestone payments become payable.
- Potential dilution from 5.0 million outstanding stock options and the loan’s conversion feature; also review the company’s disclosed PFIC uncertainty for U.S. investors.